相关实验视频

Updated: Jul 1, 2025

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

维生素D3干预的最新进展,以消灭杆菌感染

Peng-Fei Ma¹, Lin Zhuo¹, Li-Ping Yuan²

¹Department of Gastroenterology, Children's Hospital of Fudan University at Anhui (Anhui Provincial Children's Hospital), Hefei, Anhui, People's Republic of China.

Journal of multidisciplinary healthcare

|March 4, 2024

概括

维生素D3 (VitD3) 在对抗药物耐药的Helicobacter pylori (HP) 儿童感染方面显示出有前途. 这种方法通过减少炎症和促进抗微生物反应,为HP根除提供了新的策略.

科学领域:

儿科儿科儿科
微生物学微生物学
免疫学免疫学免疫学

背景情况:

全球范围内,Helicobacter pylori (HP) 感染在儿童中普遍存在,在中国的发病率为30%至60%.
肝炎感染会对儿童的生长,发育和多个器官系统产生负面影响.
抗生素耐药性增加和有限的治疗选择阻碍了儿童患者有效的HP根除.

研究的目的:

调查维生素D3 (VitD3) 作为治疗药物耐药Helicobacter pylori (HP) 在儿童中的治疗剂的潜力.
探索VitD3可以缓解HP诱导的炎症和促进根除的机制.

主要方法:

这项研究重点关注维生素D3已知的抗炎和免疫调节特性.
探索的机制包括VitD3在调节免疫反应中的作用,刺激抗微生物 (AMP) 分泌,以及影响离子 (Ca2+) 流入以恢复 lysosomal 酸化.

主要成果:

维生素D3显示出降低HP诱导的胃粘膜炎症的潜力.
VitD3可能通过免疫调节和增强的抗菌活性促进HP的根除.
这项研究强调了VitD3恢复 lysosomal 酸化的能力,这是对抗细胞内病原体的关键因素.

结论:

维生素D3为在儿童中根除耐药Helicobacter pylori菌株提供了一种新的治疗策略.
维特D3的多方面的机制为传统抗生素疗法提供了一个有希望的替代方案或辅助方案.
对VitD3的进一步研究可能会改善儿科HP感染的治疗结果.

关键词:

支持的营销策略 (AMPs)在Ca2+通道中.在Helicobacter Pylori的研究中,免疫反应的免疫反应.维生素D3是维生素D3的重要组成部分.

更多相关视频

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode

Published on: June 18, 2016

相关概念视频

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...